
News|Videos|November 11, 2025
Updated Results from the EDGE-Gastric Arm A1 Study
Author(s)Yelena Y. Janjigian, MD
Summarize long-term results from the phase 2 EDGE-Gastric Arm A1 study evaluating domvanalimab (anti-TIGIT) + zimberelimab (anti-PD-1) + FOLFOX as first-line therapy for advanced HER2-negative gastric, GEJ, or esophageal adenocarcinoma. Key data shown include ORR, PFS, OS, and safety outcomes, demonstrating encouraging clinical activity and manageable toxicity, along with context regarding the ongoing phase 3 STAR-221 trial.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































